Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

Frontiers Identification of a Prognostic Clinical Score for

A pilot study of camrelizumab with docetaxel and cisplatin for the

Durvalumab with or without tremelimumab versus the EXTREME regimen

Induction chemotherapy with docetaxel, cisplatin and 5

The dogma of cetuximab in advanced squamous cell carcinoma of the

Primary chemoradiation with cisplatin versus cetuximab for locally

Systemic Treatment Sequencing and Prediction of First-line Therapy

Full article: Cost-effectiveness of pembrolizumab for the first

Cancers, Free Full-Text